• Ipsen co-opted Mariette Finet to its board, effective immediately, replacing Michèle Ollier, who resigned on Aug. 1.
• Finet, a physician, has 35+ years in healthcare, pharmaceuticals, and life sciences, including roles at Laboratoires Beaufour and Ipsen.
• She has advised Mayroy and Highrock since 2007 on investment analysis and portfolio oversight in pharma, MedTech, and life sciences.
• The board also appointed Finet to the Board Portfolio Committee, replacing Ollier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180325PRIMZONECNPR____1001263399) on September 18, 2026, and is solely responsible for the information contained therein.